

# Harikrishna Nakshatri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1857165/publications.pdf>

Version: 2024-02-01

186  
papers

15,627  
citations

16437

64  
h-index

17580

121  
g-index

195  
all docs

195  
docs citations

195  
times ranked

18931  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acquisition, processing, and single-cell analysis of normal human breast tissues from a biobank. STAR Protocols, 2022, 3, 101047.	0.5	6
2	Tumor collection/processing under physioxia uncovers highly relevant signaling networks and drug sensitivity. Science Advances, 2022, 8, eabh3375.	4.7	27
3	Aberrant epigenetic and transcriptional events associated with breast cancer risk. Clinical Epigenetics, 2022, 14, 21.	1.8	14
4	FAM83A is a potential biomarker for breast cancer initiation. Biomarker Research, 2022, 10, 8.	2.8	9
5	Abstract P3-14-13: Metabolic links to socioeconomic stresses uniquely affecting race in normal breast tissue at risk for breast cancer. Cancer Research, 2022, 82, P3-14-13-P3-14-13.	0.4	0
6	Skeletal muscle-specific overexpression of miR-486 limits mammary tumor-induced skeletal muscle functional limitations. Molecular Therapy - Nucleic Acids, 2022, 28, 231-248.	2.3	5
7	Aging-associated skeletal muscle defects in HER2/Neu transgenic mammary tumour model. JCSM Rapid Communications, 2021, 4, 24-39.	0.6	5
8	Nonlinear relationship between chromatin accessibility and estradiol-regulated gene expression. Oncogene, 2021, 40, 1332-1346.	2.6	12
9	Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer. Cancers, 2021, 13, 369.	1.7	35
10	A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) technology: Development of targeted apoptosis initiators for cancer treatment. PLoS ONE, 2021, 16, e0225869.	1.1	4
11	Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-grade Serous Ovarian Carcinoma. Molecular Cancer Research, 2021, 19, 1168-1181.	1.5	11
12	A single-cell atlas of the healthy breast tissues reveals clinically relevant clusters of breast epithelial cells. Cell Reports Medicine, 2021, 2, 100219.	3.3	48
13	Mechanical tibial loading remotely suppresses brain tumors by dopamine-mediated downregulation of CCN4. Bone Research, 2021, 9, 26.	5.4	4
14	Overexpression of Lrp5 enhanced the anti-breast cancer effects of osteocytes in bone. Bone Research, 2021, 9, 32.	5.4	25
15	Bidirectional Regulatory Cross-Talk between Cell Context and Genomic Aberrations Shapes Breast Tumorigenesis. Molecular Cancer Research, 2021, 19, 1802-1817.	1.5	6
16	Hormonally Regulated Myogenic miR-486 Influences Sex-specific Differences in Cancer-induced Skeletal Muscle Defects. Endocrinology, 2021, 162, .	1.4	4
17	Building a virtual summer research experience in cancer for high school and early undergraduate students: lessons from the COVID-19 pandemic. BMC Medical Education, 2021, 21, 422.	1.0	7
18	Antitumor properties of novel sesquiterpene lactone analogs as NF- $\kappa$ B inhibitors that bind to the IKK $\beta$ ubiquitin-like domain (ULD). European Journal of Medicinal Chemistry, 2021, 224, 113675.	2.6	4

#	ARTICLE	IF	CITATIONS
19	Aged Breast Extracellular Matrix Drives Mammary Epithelial Cells to an Invasive and Cancer-Like Phenotype. <i>Advanced Science</i> , 2021, 8, e2100128.	5.6	19
20	Cell competition and tumor heterogeneity. <i>Seminars in Cancer Biology</i> , 2020, 63, 1-10.	4.3	26
21	regSNPs-ASB: A Computational Framework for Identifying Allele-Specific Transcription Factor Binding From ATAC-seq Data. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 886.	2.0	5
22	Breast Cancer Cell Detection and Characterization from Breast Milk-Derived Cells. <i>Cancer Research</i> , 2020, 80, 4828-4839.	0.4	11
23	In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. <i>PLoS Genetics</i> , 2020, 16, e1008808.	1.5	27
24	Skeletal loading regulates breast cancer-associated osteolysis in a loading intensity-dependent fashion. <i>Bone Research</i> , 2020, 8, 9.	5.4	40
25	Systemic Actions of Breast Cancer Facilitate Functional Limitations. <i>Cancers</i> , 2020, 12, 194.	1.7	9
26	Breast Heterogeneity: Obstacles to Developing Universal Biomarkers of Breast Cancer Initiation and Progression. <i>Journal of the American College of Surgeons</i> , 2020, 231, 85-96.	0.2	2
27	Flower isoforms promote competitive growth in cancer. <i>Nature</i> , 2019, 572, 260-264.	13.7	96
28	Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer. <i>Nature Communications</i> , 2019, 10, 2860.	5.8	18
29	Dual TGF $\beta$ 2/BMP Pathway Inhibition Enables Expansion and Characterization of Multiple Epithelial Cell Types of the Normal and Cancerous Breast. <i>Molecular Cancer Research</i> , 2019, 17, 1556-1570.	1.5	16
30	Genetic Ancestry-dependent Differences in Breast Cancer-induced Field Defects in the Tumor-adjacent Normal Breast. <i>Clinical Cancer Research</i> , 2019, 25, 2848-2859.	3.2	23
31	Interferon- $\beta$ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer. <i>Npj Precision Oncology</i> , 2019, 3, 32.	2.3	21
32	Attraction and Compaction of Migratory Breast Cancer Cells by Bone Matrix Proteins through Tumor-Osteocyte Interactions. <i>Scientific Reports</i> , 2018, 8, 5420.	1.6	23
33	An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. <i>Clinical Cancer Research</i> , 2018, 24, 3163-3175.	3.2	93
34	Mutational landscape of RNA-binding proteins in human cancers. <i>RNA Biology</i> , 2018, 15, 115-129.	1.5	87
35	A system for detecting high impact-low frequency mutations in primary tumors and metastases. <i>Oncogene</i> , 2018, 37, 185-196.	2.6	21
36	Osteocyte-Driven Downregulation of Snail Restrains Effects of Drd2 Inhibitors on Mammary Tumor Cells. <i>Cancer Research</i> , 2018, 78, 3865-3876.	0.4	43

#	ARTICLE	IF	CITATIONS
37	Normal Breast-Derived Epithelial Cells with Luminal and Intrinsic Subtype-Enriched Gene Expression Document Interindividual Differences in Their Differentiation Cascade. <i>Cancer Research</i> , 2018, 78, 5107-5123.	0.4	42
38	Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling. <i>International Journal of Oncology</i> , 2018, 53, 1001-1012.	1.4	11
39	Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis. <i>Breast Cancer Research</i> , 2018, 20, 35.	2.2	14
40	MMB triazole analogs are potent NF- $\kappa$ B inhibitors and anti-cancer agents against both hematological and solid tumor cells. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 562-581.	2.6	34
41	Inhibiting checkpoint kinase 1 protects bone from bone resorption by mammary tumor in a mouse model. <i>Oncotarget</i> , 2018, 9, 9364-9378.	0.8	13
42	Microfluidic channel for characterizing normal and breast cancer cells. <i>Journal of Micromechanics and Microengineering</i> , 2017, 27, 035017.	1.5	28
43	Individualized Breast Cancer Characterization through Single-Cell Analysis of Tumor and Adjacent Normal Cells. <i>Cancer Research</i> , 2017, 77, 2759-2769.	0.4	16
44	RareVar: A Framework for Detecting Low-Frequency Single-Nucleotide Variants. <i>Journal of Computational Biology</i> , 2017, 24, 637-646.	0.8	5
45	Inhibitory Effects of Dopamine Receptor D1 Agonist on Mammary Tumor and Bone Metastasis. <i>Scientific Reports</i> , 2017, 7, 45686.	1.6	35
46	Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2747-2758.	1.9	19
47	Reduction in Migratory Phenotype in a Metastasized Breast Cancer Cell Line via Downregulation of S100A4 and GRM3. <i>Scientific Reports</i> , 2017, 7, 3459.	1.6	23
48	A spectrum graph-based protein sequence filtering algorithm for proteoform identification by top-down mass spectrometry. , 2017, 2017, 222-229.		5
49	Inflammation-associated microRNA changes in circulating exosomes of heart failure patients. <i>BMC Research Notes</i> , 2017, 10, 751.	0.6	40
50	Will PI3K-targeted therapies for cancer become a reality?. <i>Translational Cancer Research</i> , 2017, 6, S371-S375.	0.4	0
51	Distinct Effects of Adipose-Derived Stem Cells and Adipocytes on Normal and Cancer Cell Hierarchy. <i>Molecular Cancer Research</i> , 2016, 14, 660-671.	1.5	9
52	Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer. <i>Cancer Research</i> , 2016, 76, 3989-4001.	0.4	27
53	Statistical modeling for sensitive detection of low-frequency single nucleotide variants. <i>BMC Genomics</i> , 2016, 17, 514.	1.2	4
54	Ethnicity-Dependent and -Independent Heterogeneity in Healthy Normal Breast Hierarchy Impacts Tumor Characterization. <i>Scientific Reports</i> , 2015, 5, 13526.	1.6	45

#	ARTICLE	IF	CITATIONS
55	NF- $\kappa$ B-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT. Cell Death and Disease, 2015, 6, e1608-e1608.	2.7	48
56	TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis. Breast Cancer Research and Treatment, 2015, 152, 519-531.	1.1	30
57	HOXB7 Is an ER $\alpha$ Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance. Cancer Discovery, 2015, 5, 944-959.	7.7	72
58	Essential Components of Cancer Education. Cancer Research, 2015, 75, 5202-5205.	0.4	10
59	Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells. Oncotarget, 2015, 6, 12682-12696.	0.8	52
60	PROGeneV2: enhancements on the existing database. BMC Cancer, 2014, 14, 970.	1.1	417
61	The mushroom Ganoderma lucidum suppresses breast-to-lung cancer metastasis through the inhibition of pro-invasive genes. International Journal of Oncology, 2014, 44, 2009-2015.	1.4	41
62	Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain. Journal of Pathology, 2014, 232, 369-381.	2.1	98
63	Cancer Affects microRNA Expression, Release, and Function in Cardiac and Skeletal Muscle. Cancer Research, 2014, 74, 4270-4281.	0.4	44
64	MicroRNA and Cancer Drug Resistance. , 2014, , 305-326.		0
65	Interplay between estrogen receptor and AKT in Estradiol-induced alternative splicing. BMC Medical Genomics, 2013, 6, 21.	0.7	25
66	Identification of FDA-approved Drugs Targeting Breast Cancer Stem Cells Along With Biomarkers of Sensitivity. Scientific Reports, 2013, 3, 2530.	1.6	53
67	PROGene: gene expression based survival analysis web application for multiple cancers. Journal of Clinical Bioinformatics, 2013, 3, 22.	1.2	140
68	Role of AKT isotypes in breast cancer. Journal of Pathology, 2013, 229, e1.	2.1	6
69	ANTXR1, a Stem Cell-Enriched Functional Biomarker, Connects Collagen Signaling to Cancer Stem-like Cells and Metastasis in Breast Cancer. Cancer Research, 2013, 73, 5821-5833.	0.4	104
70	HOXB13 Mediates Tamoxifen Resistance and Invasiveness in Human Breast Cancer by Suppressing ER $\alpha$ and Inducing IL-6 Expression. Cancer Research, 2013, 73, 5449-5458.	0.4	80
71	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of breast cancer management. Breast Cancer Management, 2013, 2, 189-191.	0.2	0
72	Journal Watch: Our expert highlights the most important research articles across the spectrum of topics relevant to the field of breast cancer management. Breast Cancer Management, 2013, 2, 97-99.	0.2	0

#	ARTICLE	IF	CITATIONS
73	Journal Watch: Our expert highlights the most important research articles across a spectrum of topics relevant to the field of breast cancer management.. Breast Cancer Management, 2012, 1, 117-118.	0.2	0
74	Breast-cancer stem cellsâ€”beyond semantics. Lancet Oncology, The, 2012, 13, e43-e48.	5.1	137
75	Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse. Cancer Nanotechnology, 2012, 3, 47-54.	1.9	132
76	PROGmiR: a tool for identifying prognostic miRNA biomarkers in multiple cancers using publicly available data. Journal of Clinical Bioinformatics, 2012, 2, 23.	1.2	58
77	FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Research and Treatment, 2012, 131, 881-890.	1.1	111
78	Virtual Screening Targeting the Urokinase Receptor, Biochemical and Cell-Based Studies, Synthesis, Pharmacokinetic Characterization, and Effect on Breast Tumor Metastasis. Journal of Medicinal Chemistry, 2011, 54, 7193-7205.	2.9	32
79	Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Research, 2011, 13, R86.	2.2	83
80	FOXA1 (forkhead box A1). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	1
81	High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology, 2011, 58, 766-772.	1.6	57
82	Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene, 2011, 30, 1290-1301.	2.6	115
83	Biomarkers for breast cancer stem cells: the challenges ahead. Biomarkers in Medicine, 2011, 5, 661-671.	0.6	17
84	A large, consistent plasma proteomics data set from prospectively collected breast cancer patient and healthy volunteer samples. Journal of Translational Medicine, 2011, 9, 80.	1.8	12
85	A water soluble parthenolide analog suppresses <i>in vivo</i> tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF- $\kappa$ B and generating reactive oxygen species. International Journal of Cancer, 2011, 128, 2481-2494.	2.3	72
86	Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Research and Treatment, 2010, 123, 97-108.	1.1	165
87	SLUG/SNAI2 and Tumor Necrosis Factor Generate Breast Cells With CD44+/CD24- Phenotype. BMC Cancer, 2010, 10, 411.	1.1	155
88	A water-soluble parthenolide analogue suppresses <i>in vivo</i> prostate cancer growth by targeting NF- $\kappa$ B and generating reactive oxygen species. Prostate, 2010, 70, 1074-1086.	1.2	60
89	Prognosis of Hormone-Dependent Breast Cancers: Implications of the Presence of Dysfunctional Transcriptional Networks Activated by Insulin via the Immune Transcription Factor T-bet. Cancer Research, 2010, 70, 685-696.	0.4	23
90	ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer. Cancer Biology and Therapy, 2010, 10, 600-614.	1.5	15

#	ARTICLE	IF	CITATIONS
91	Loss of ER $\alpha$ and FOXA1 expression in a progression model of luminal type breast cancer: Insights from PyMT transgenic mouse model. <i>Oncology Reports</i> , 2010, 24, 1233-9.	1.2	24
92	Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. <i>Modern Pathology</i> , 2010, 23, 270-275.	2.9	43
93	Subcellular Localization of Activated AKT in Estrogen Receptor- and Progesterone Receptor-Expressing Breast Cancers. <i>American Journal of Pathology</i> , 2010, 176, 2139-2149.	1.9	40
94	Radiation resistance in breast cancer: are CD44+/CD24-/proteasomelow/PKH26+cells to blame?. <i>Breast Cancer Research</i> , 2010, 12, 105.	2.2	22
95	Breast Cancer Stem Cells and Intrinsic Subtypes: Controversies Rage On. <i>Current Stem Cell Research and Therapy</i> , 2009, 4, 50-60.	0.6	102
96	Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. <i>Journal of Clinical Pathology</i> , 2009, 62, 6-12.	1.0	74
97	Epithelial-to-Mesenchymal Transition and Ovarian Tumor Progression Induced by Tissue Transglutaminase. <i>Cancer Research</i> , 2009, 69, 9192-9201.	0.4	114
98	Obesity potentiates the growth and dissemination of pancreatic cancer. <i>Surgery</i> , 2009, 146, 258-263.	1.0	118
99	Intrinsic subtype-associated changes in the plasma proteome in breast cancer. <i>Proteomics - Clinical Applications</i> , 2009, 3, 1305-1313.	0.8	13
100	NF- $\kappa$ B inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. <i>Cancer Letters</i> , 2009, 278, 145-155.	3.2	67
101	Estradiol-regulated microRNAs control estradiol response in breast cancer cells. <i>Nucleic Acids Research</i> , 2009, 37, 4850-4861.	6.5	310
102	FOXA1 in breast cancer. <i>Expert Reviews in Molecular Medicine</i> , 2009, 11, e8.	1.6	60
103	Correlation of FOXA1 expression with Oncotype Dx recurrence scores. <i>Journal of Clinical Oncology</i> , 2009, 27, 11058-11058.	0.8	0
104	Amplified in breast cancer 1 expression in breast cancer. <i>Histopathology</i> , 2008, 53, 634-641.	1.6	10
105	Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. <i>Carcinogenesis</i> , 2008, 29, 25-34.	1.3	71
106	AKT Alters Genome-Wide Estrogen Receptor $\alpha$ Binding and Impacts Estrogen Signaling in Breast Cancer. <i>Molecular and Cellular Biology</i> , 2008, 28, 7487-7503.	1.1	87
107	Striatin-3 $\beta$ inhibits estrogen receptor activity by recruiting a protein phosphatase. <i>Journal of Molecular Endocrinology</i> , 2008, 40, 199-210.	1.1	12
108	Antimyeloma Effects of a Sesquiterpene Lactone Parthenolide. <i>Clinical Cancer Research</i> , 2008, 14, 1814-1822.	3.2	37

#	ARTICLE	IF	CITATIONS
109	Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. <i>Carcinogenesis</i> , 2008, 29, 1893-1900.	1.3	88
110	The Platelet-derived Growth Factor Receptor $\alpha$ Is Destabilized by Geldanamycins in Cancer Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 445-453.	1.6	56
111	Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. <i>Journal of Clinical Pathology</i> , 2007, 61, 327-332.	1.0	101
112	Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1736-1744.	1.9	39
113	Enhanced Peritoneal Ovarian Tumor Dissemination by Tissue Transglutaminase. <i>Cancer Research</i> , 2007, 67, 7194-7202.	0.4	108
114	FOXA1 Expression in Breast Cancer—Correlation with Luminal Subtype A and Survival. <i>Clinical Cancer Research</i> , 2007, 13, 4415-4421.	3.2	220
115	2-Methoxyestradiol Inhibits the Anaphase-Promoting Complex and Protein Translation in Human Breast Cancer Cells. <i>Cancer Research</i> , 2007, 67, 702-708.	0.4	24
116	Effect of Celecoxib and Novel Agent LC-1 in a Hamster Model of Lung Cancer. <i>Journal of Surgical Research</i> , 2007, 143, 169-176.	0.8	7
117	FOXA1 as a therapeutic target for breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 507-514.	1.5	61
118	Identity Profiling of Cell Surface Markers by Multiplex Gold Nanorod Probes. <i>Nano Letters</i> , 2007, 7, 2300-2306.	4.5	144
119	Parthenolide Sensitizes Cells to X-Ray-Induced Cell Killing through Inhibition of NF- $\kappa$ B and Split-Dose Repair. <i>Radiation Research</i> , 2007, 168, 689-697.	0.7	32
120	NF- $\kappa$ B represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. <i>Oncogene</i> , 2007, 26, 711-724.	2.6	545
121	Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. <i>Oncogene</i> , 2007, 26, 3329-3337.	2.6	105
122	MOZ and MOZ-CBP cooperate with NF- $\kappa$ B to activate transcription from NF- $\kappa$ B-dependent promoters. <i>Experimental Hematology</i> , 2007, 35, 1782-1792.	0.2	31
123	CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. <i>Breast Cancer Research</i> , 2006, 8, R59.	2.2	839
124	Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. <i>Prostate</i> , 2006, 66, 1498-1511.	1.2	44
125	Negative regulation of MHC class II gene expression by CXCR4. <i>Experimental Hematology</i> , 2006, 34, 1085-1092.	0.2	19
126	Effects of HIV Protease Inhibitor Ritonavir on Akt-Regulated Cell Proliferation in Breast Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 1883-1896.	3.2	100



#	ARTICLE	IF	CITATIONS
127	The Sesquiterpene Lactone Parthenolide Induces Apoptosis and Overcomes the Protective Effect of the Bone Marrow Microenvironment in Human Multiple Myeloma Cells.. <i>Blood</i> , 2006, 108, 5058-5058.	0.6	1
128	Prediction of long-term survival using expression of FOXA1, a determinant of estrogen response domains in breast cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 539-539.	0.8	1
129	TNF $\alpha$ resistance in MCF-7 breast cancer cells is associated with altered subcellular localization of p21CIP1 and p27KIP1. <i>Cell Death and Differentiation</i> , 2005, 12, 98-100.	5.0	12
130	The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1 $\alpha$ /CXCL12. <i>Carcinogenesis</i> , 2005, 26, 1706-1715.	1.3	61
131	The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells. <i>Carcinogenesis</i> , 2005, 26, 900-907.	1.3	40
132	Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor- $\kappa$ B pathway in pancreatic carcinoma cells. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 587-594.	1.9	108
133	The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1004-1012.	1.9	145
134	Inhibiting Proteasomal Proteolysis Sustains Estrogen Receptor- $\alpha$ Activation. <i>Molecular Endocrinology</i> , 2004, 18, 2603-2615.	3.7	78
135	Nuclear Factor- $\kappa$ B Is Constitutively Activated in Prostate Cancer In vitro and Is Overexpressed in Prostatic Intraepithelial Neoplasia and Adenocarcinoma of the Prostate. <i>Clinical Cancer Research</i> , 2004, 10, 5501-5507.	3.2	157
136	Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. <i>Oncogene</i> , 2004, 23, 7330-7344.	2.6	141
137	Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function. <i>British Journal of Cancer</i> , 2004, 90, 853-859.	2.9	28
138	Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. <i>Investigational New Drugs</i> , 2004, 22, 299-305.	1.2	109
139	Interleukin-1 $\alpha$ Promotes Tumor Growth and Cachexia in MCF-7 Xenograft Model of Breast Cancer. <i>American Journal of Pathology</i> , 2003, 163, 2531-2541.	1.9	72
140	NF- $\kappa$ B Promotes Breast Cancer Cell Migration and Metastasis by Inducing the Expression of the Chemokine Receptor CXCR4. <i>Journal of Biological Chemistry</i> , 2003, 278, 21631-21638.	1.6	568
141	Identification of signal transduction pathways involved in constitutive NF- $\kappa$ B activation in breast cancer cells. <i>Oncogene</i> , 2002, 21, 2066-2078.	2.6	114
142	NF- $\kappa$ B and breast cancer. <i>Current Problems in Cancer</i> , 2002, 26, 282-309.	1.0	62
143	Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor $\alpha$ . <i>Journal of Biological Chemistry</i> , 2001, 276, 9817-9824.	1.6	831
144	Fusion AML1 transcript in a radiation-associated leukemia results in a truncated inhibitory AML1 protein. <i>Blood</i> , 2001, 97, 2168-2170.	0.6	33

#	ARTICLE	IF	CITATIONS
145	Transformation of interleukin-3â€“dependent cells without participation of Stat5/bcl-xL: cooperation of akt with raf/erk leads to p65 nuclear factor Î²â€“mediated antiapoptosis involving c-IAP2. <i>Blood</i> , 2001, 98, 2508-2517.	0.6	37
146	Repression of GADD153/CHOP by NF-Î²B: a possible cellular defense against endoplasmic reticulum stress-induced cell death. <i>Oncogene</i> , 2001, 20, 2178-2185.	2.6	104
147	Cutting Edge: IL-17F, a Novel Cytokine Selectively Expressed in Activated T Cells and Monocytes, Regulates Angiogenesis and Endothelial Cell Cytokine Production. <i>Journal of Immunology</i> , 2001, 167, 4137-4140.	0.4	320
148	The Platelet-activating Factor Receptor Protects Epidermal Cells from Tumor Necrosis Factor (TNF) Î± and TNF-related Apoptosis-inducing Ligand-induced Apoptosis through an NF-Î²B-dependent Process. <i>Journal of Biological Chemistry</i> , 2001, 276, 45548-45554.	1.6	41
149	Repression of transforming-growth-factor-Î²2-mediated transcription by nuclear factor Î²B. <i>Biochemical Journal</i> , 2000, 348, 591.	1.7	37
150	Repression of transforming-growth-factor-Î²2-mediated transcription by nuclear factor Î²B. <i>Biochemical Journal</i> , 2000, 348, 591-596.	1.7	111
151	Paclitaxel sensitivity of breast cancer cells with constitutively active NF-Î²B is enhanced by Î²BÎ± super-repressor and parthenolide. <i>Oncogene</i> , 2000, 19, 4159-4169.	2.6	277
152	The Orphan Receptor COUP-TFII Regulates G2/M Progression of Breast Cancer Cells by Modulating the Expression/Activity of p21WAF1/CIP1, Cyclin D1, and cdk2. <i>Biochemical and Biophysical Research Communications</i> , 2000, 270, 1144-1153.	1.0	35
153	Cancer Cell-Derived Interleukin 1Î± Contributes to Autocrine and Paracrine Induction of Pro-metastatic Genes in Breast Cancer. <i>Biochemical and Biophysical Research Communications</i> , 2000, 275, 60-62.	1.0	64
154	Negative Regulation of Transactivation Function but Not DNA Binding of NF-Î²B and AP-1 by Î²BÎ±21 in Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 1999, 274, 18827-18835.	1.6	56
155	Cloning of BRAK, a Novel Divergent CXC Chemokine Preferentially Expressed in Normal versus Malignant Cells. <i>Biochemical and Biophysical Research Communications</i> , 1999, 255, 703-706.	1.0	177
156	Binding and activation of the human aldehyde dehydrogenase 2 promoter by hepatocyte nuclear factor 4. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1998, 1399, 181-186.	2.4	32
157	Multiple parameters determine the specificity of transcriptional response by nuclear receptors HNF-4, ARP-1, PPAR, RAR and RXR through common response elements. <i>Nucleic Acids Research</i> , 1998, 26, 2491-2499.	6.5	92
158	Regulation of the c-jun Gene in p210 BCR-ABL Transformed Cells Corresponds With Activity of JNK, the c-jun N-Terminal Kinase. <i>Blood</i> , 1998, 92, 2450-2460.	0.6	47
159	NF-Î²B activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1Î±. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 6971-6976.	3.3	78
160	Regulation of the c-jun Gene in p210 BCR-ABL Transformed Cells Corresponds With Activity of JNK, the c-jun N-Terminal Kinase. <i>Blood</i> , 1998, 92, 2450-2460.	0.6	6
161	Constitutive Activation of NF-Î²B during Progression of Breast Cancer to Hormone-Independent Growth. <i>Molecular and Cellular Biology</i> , 1997, 17, 3629-3639.	1.1	790
162	Differential Effect of Nonidet P40 on DNA Binding of Transcription Factors. <i>Analytical Biochemistry</i> , 1997, 249, 103-104.	1.1	9

#	ARTICLE	IF	CITATIONS
163	Isolation of retinoic acid-repressed genes from P19 embryonal carcinoma cells. <i>Gene</i> , 1996, 174, 79-84.	1.0	31
164	CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 3967-3971.	3.3	101
165	Differential Whole-Cell Extract Preparation and Electrophoretic Mobility Shift Assay to Evaluate the Effect of Tyrosine Phosphatases on DNA Binding Activity of Transcription Factors. <i>Analytical Biochemistry</i> , 1996, 236, 178-181.	1.1	3
166	Subunit Association and DNA Binding Activity of the Heterotrimeric Transcription Factor NF-Y Is Regulated by Cellular Redox. <i>Journal of Biological Chemistry</i> , 1996, 271, 28784-28791.	1.6	88
167	Interaction of Oct-1 with TFIIB. <i>Journal of Biological Chemistry</i> , 1995, 270, 19613-19623.	1.6	56
168	Stage and tissue-specific expression of the alcohol dehydrogenase 1 (Adh-1) gene during mouse development. <i>Developmental Dynamics</i> , 1994, 199, 199-213.	0.8	45
169	The directly repeated RG(G/T)TCA motifs of the rat and mouse cellular retinol-binding protein II genes are promiscuous binding sites for RAR, RXR, HNF-4, and ARP-1 homo- and heterodimers.. <i>Journal of Biological Chemistry</i> , 1994, 269, 890-902.	1.6	139
170	The directly repeated RG(G/T)TCA motifs of the rat and mouse cellular retinol-binding protein II genes are promiscuous binding sites for RAR, RXR, HNF-4, and ARP-1 homo- and heterodimers. <i>Journal of Biological Chemistry</i> , 1994, 269, 890-902.	1.6	121
171	Retinoic Acid Signal Transduction Pathways. <i>Annals of the New York Academy of Sciences</i> , 1993, 684, 19-34.	1.8	45
172	RARs and RXRs: evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo.. <i>EMBO Journal</i> , 1993, 12, 2349-2360.	3.5	275
173	RARs and RXRs: evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo. <i>EMBO Journal</i> , 1993, 12, 2349-60.	3.5	82
174	Retinoid receptors and binding proteins. <i>Journal of Cell Science</i> , 1992, 1992, 69-76.	1.2	32
175	Promoter context- and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors. <i>Cell</i> , 1992, 70, 1007-1019.	13.5	365
176	Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. <i>Cell</i> , 1992, 68, 377-395.	13.5	1,218
177	The first 124 nucleotides of the E7 coding sequences of HPV16 can render the HPV11 genome transformation competent. <i>Virology</i> , 1992, 186, 348-351.	1.1	12
178	A retinoic acid response element is present in the mouse cellular retinol binding protein I (mCRBPI) promoter.. <i>EMBO Journal</i> , 1991, 10, 2223-2230.	3.5	226
179	Mouse retinoic acid receptor alpha 2 isoform is transcribed from a promoter that contains a retinoic acid response element.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 10138-10142.	3.3	204
180	Activity and enhancer binding factors for BK virus regulatory elements in differentiating embryonal carcinoma cells. <i>Virology</i> , 1991, 183, 374-380.	1.1	9

#	ARTICLE	IF	CITATIONS
181	A retinoic acid response element is present in the mouse cellular retinol binding protein I (mCRBPI) promoter. <i>EMBO Journal</i> , 1991, 10, 2223-30.	3.5	68
182	Ubiquitous and cell-type-specific protein interactions with human papillomavirus type 16 and type 18 enhancers. <i>Virology</i> , 1990, 178, 92-103.	1.1	34
183	Activity and enhancer binding factors for jc virus regulatory elements in differentiating embryonal carcinoma cells. <i>Virology</i> , 1990, 177, 784-789.	1.1	18
184	Glucocorticoid-dependent oncogenic transformation by type 16 but not type 11 human papilloma virus DNA. <i>Nature</i> , 1988, 335, 832-835.	13.7	146
185	Functional role of BK virus tumor antigens in transformation. <i>Journal of Virology</i> , 1988, 62, 4613-4621.	1.5	19
186	Metabolic Links to Socioeconomic Stresses Uniquely Affecting Ancestry in Normal Breast Tissue at Risk for Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3